關於「adi-peg 20」標籤，搜尋引擎有相關的訊息討論：

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced ...。

This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have ...。

A study of ADI-PEG 20 with pemetrexed and cisplatin for advanced ...。

This study is looking at a drug called ADI-PEG 20 with pemetrexed and cisplatin to treat cancer that has spread or a fast growing brain tumour.。

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed ...。

2017年9月12日 · Patient characteristics and treatment delivered. A total of 43 patients were enrolled from Oct 2013 to Oct 2015 in Taiwan and the US. Twenty-two ...。

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or ...。

2017年5月30日 · The TRAP Phase 1 trial (NCT02029690) of ADI-PEG 20 combined with 1st-line pemetrexed (PEM) and cisplatin (CDDP) chemotherapy revealed a 94% ...。

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients ...。

Concurrent mFOLFOX6 plus ADI-PEG-20 intramuscularly at 36 mg/m 2 weekly shows an acceptable ... 7 Chi Mei Medical Center, Tainan, Taiwan, Republic of China.： 。

Phase III randomized study of second line ADI-PEG 20 plus best ...。

2018年6月1日 · Department of Medical Oncology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan. 5 Department ...： 。

Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in ...。

2020年8月15日 · Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res ...。

Intracellular expression of arginine deiminase activates the ...。

2020年7月16日 · ADI expressed in the cytosol displays higher oncolytic efficiency than ADI-PEG20 (Pegylated Arginine Deiminase by PEG 20,000).。

圖片全部顯示。

Cell Death Signaling in Cancer Biology and Treatment。

Biochemistry 20(5):1312–1318 Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADi-SS PEG 20,000 mw) inhibits human ...